Pre-challenge neutralization titers reflect post-challenge virus load in HIV-1 vaccinated chimpanzees.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Pre-challenge neutralization titers reflect post-challenge virus load in HIV-1 vaccinated chimpanzees.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 116. Unique Identifier : AIDSLINE PRIM10/93200956
Heeney J; Thiriart C; Koornstra W; Dubbes R; ten Haaft P; Delers A; Fabry L; Francotte M; von Opstal O; Culp J; et al; Laboratory of Viral Pathogenesis, ITRI-TNO, Rijswijk, The; Netherlands.

Abstract: A quantitative virus isolation assay was developed for the determination of virus load in HIV-1 infected chimpanzees. In a study designed to study immunological correlates of HIV-1 vaccine protection, two different recombinant HIV-1 envelope preparations were used. Recombinant forms of HIV-1 env gp160 and gp120 (III B isolate, BH 10 molecular clone) were produced in mammalian and insect cells respectively. The purified recombinant proteins were formulated in an oil in water emulsion vehicle with 3D-MPL immunoadjuvant. Group of 2 chimpanzees were injected with 4 doses of 100 micrograms of gp160 or gp120 or a control antigen in the same adjuvant over an eight month period. Prechallenge immunological work-up included ELISA evaluation of antibody response to the immunogen, to the BH 10 V3 loop, gp120 sCD4 binding interference assay, as well as type- and group-specific neutralizing activity. DTH responses were monitored after the second boost. Intravenous homologous challenge was performed with 10 CID50 of cell-free HIV-1 III B stock. Post-challenge follow-up included prechallenge serological assays plus quantitative virus isolation, Western blot, PCR of PBMCs, lymph node and bone marrow from protected animals. Results one year post-challenge will be presented.

Keywords: Animal Antibody Formation Blotting, Western Bone Marrow/IMMUNOLOGY Chimpansee troglodytes Enzyme-Linked Immunosorbent Assay Gene Products, env/GENETICS/*IMMUNOLOGY Genes, env HIV Antibodies/BLOOD HIV Envelope Protein gp120/GENETICS/*IMMUNOLOGY HIV-1/*IMMUNOLOGY/ISOLATION & PURIF Immunization, Secondary Lymph Nodes/IMMUNOLOGY Neutralization Tests Polymerase Chain Reaction Protein Precursors/GENETICS/*IMMUNOLOGY Vaccines, Synthetic/*IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY ABSTRACT
930630
M9361064

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .